Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

multi-epitope HER2 peptide vaccine H2NVAC

A peptide vaccine containing four immunogenic epitopes derived from the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; HER-2; ErbB2; Neu), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope HER2 peptide vaccine H2NVAC may induce a helper T-cell mediated immune response against HER2-overexpressing tumor cells. This may result in long-term immunopotentiation against HER2-expressing tumor cells by increasing the helper T-cell response. HER2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed in various cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:HER2 peptide vaccine H2NVAC
HER2 specific helper T-cell epitope vaccine H2NVAC
Code name:H2NVAC
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search